Organization | Federal University of Bahia

Federal University of Bahia Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Salvador Brazil (1946)

Organization Overview

First Clinical Trial

2002

NCT00955643

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Associate Professor, Federal University of Bahia | Camila Ribeiro de Avelar | Escola Bahiana de Medicina e Saude Publica | Federal University of Bahia | Federal University of Bahia School of Medicine | Fundação Bahiana de Infectologia | Fundação Osvaldo Cruz Bahia | Fundação Oswaldo Cruz - Instituto Aggeu Magalhães | Fundação Oswaldo Cruz, Instituto Carlos Chagas, ICC Paraná | Hospital Ana Nery - Federal University of Bahia | Hospital Universitário Professor Edgard Santos | Service of Imunology - Universitary Hospital Prof. Edgard Santos | Universitary Hospital Prof. Edgard Santos

Active Ingredients

Drugs in Phase 4 Trials (7)

acetylsalicylic acid (aspirin) (1 trial)

desogestrel (Mercilon) (1 trial)

dolutegravir (tivicay) (2 trials)

emtricitabine (emtriva) (1 trial)

lamivudine (epivir) (2 trials)

procaine benzylpenicillin (novocaine) (1 trial)

tenofovir (viread) (1 trial)

Drugs in Phase 3 Trials (30)

amphotericin b (fungizone) (1 trial)

antimony (4 trials)

bortezomib (velcade) (1 trial)

citalopram (celexa) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dexamethasone (1 trial)

efavirenz (sustiva) (1 trial)

fluconazole (diflucan) (1 trial)

lopinavir (Kaletra) (1 trial)

maprotiline (ludiomil) (1 trial)

meglumine (2 trials)

meglumine antimoniate (3 trials)

miltefosine (impavido) (3 trials)

paroxetine (paxil) (1 trial)

pentoxifylline (trental) (2 trials)

raltegravir (isentress) (2 trials)

rimabotulinumtoxinB (Myobloc) (1 trial)

ritonavir (Norvir) (1 trial)

rivaroxaban (xarelto) (1 trial)

rivastigmine (exelon) (1 trial)

sargramostim (leukine) (2 trials)

sertraline (zoloft) (1 trial)

sildenafil (viagra) (1 trial)

sodium chloride (1 trial)

thalidomide (Thalomid) (1 trial)

tofacitinib (xeljanz) (1 trial)

trazodone (desyrel) (1 trial)

venlafaxine (effexor) (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Phase 2 Trials (12)

allogeneic adipose derived mesenchymal stem cell (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

COVID-19 convalescent plasma (1 trial)

ethambutol (myambutol) (1 trial)

fordesine (1 trial)

isoniazid (nydrazid) (1 trial)

methylglucamine antimoniate (2 trials)

pyrazinamide (Aldinamide) (1 trial)

rifampin (1 trial)

sacubitril (Entresto) (1 trial)

valsartan (diovan) (1 trial)

Drugs in Phase 1 Trials (2)

autologous mononuclear stem cell (1 trial)

propantheline bromide (pro-banthine) (1 trial)

Drugs in Other Trials (6)

acetylcysteine (mucomyst) (1 trial)

cow milk (2 trials)

ezetimibe (zetia) (1 trial)

oxygen (1 trial)

silymarin (1 trial)

simvastatin (zocor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alzheimer Disease (Phase 3)

Anemia, Sickle Cell (Phase 4)

Blood Coagulation Disorders (Phase 3)

Chagas Disease (Phase 4)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Diarrhea (Phase 3)

Headache (Phase 3)

Heart Diseases (Phase 3)

Heart Failure (Phase 4)

Heart Valve Diseases (Phase 3)

Hemostatic Disorders (Phase 3)

HIV Infections (Phase 3)

Hyperalgesia (Phase 3)

Hypertension (Phase 2)

Immune System Diseases (Phase 3)

Infections (Phase 3)

Leg Ulcer (Phase 1)

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Multiple Myeloma (Phase 3)

Muscle Spasticity (Phase 3)

Necrosis (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Osteonecrosis (Phase 2)

Paraparesis (Phase 3)

Paraparesis, Spastic (Phase 3)

Paraparesis, Tropical Spastic (Phase 3)

Pneumonia (Phase 4)

Respiratory Tract Infections (Phase 3)

Skin Ulcer (Phase 1)

Tuberculosis (Phase 2)

Tuberculosis, Pulmonary (Phase 2)

Ulcer (Phase 1)

Urinary Bladder, Overactive (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 39
# of Trial APIs: 57